Skip to content

Newsroom

type
year
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

1/8/2026 Flagging notifications
Illustration image.png

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)

1/8/2026 Press release
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

1/7/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

1/7/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/31/2025 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/30/2025 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/23/2025 Flagging notifications
Orion_IM-team_Paakuva_1500x844 (1).jpg

Orion’s IT team builds solutions that keep research and production moving

12/22/2025 We are Orion Pharma
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/15/2025 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/9/2025 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/8/2025 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/5/2025 Flagging notifications
Orionpharma_Research_Ecosystem_Paakuva_1500x844.png

Orion strengthens Finland’s pharmaceutical research through Veturi Research Ecosystem

12/4/2025 Science and Partnering
Illustration image.png

Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025

12/3/2025 Stock exchange release
Illustration image.png

71,498 Orion Corporation A shares converted into B shares

11/27/2025 Stock exchange release
orionpharma_professional_CatherineOpio_1500x844.jpg

“Behind every trial is a real person” – Catherine Opio builds Orion’s clinical operations in the US

11/20/2025 We are Orion Pharma
ORION_10_10_2025_Sami_Tuoriniemi-3987.jpg

Orion receives award for international growth from the President of the Republic of Finland

11/14/2025 Orion Pharma and Society
Illustration image.png

Orion receives award for international growth from the President of the Republic of Finland

11/14/2025 Press release